��������

Dr. Massimo Fantini joined Precision Biologics, Inc. as Senior Scientist in December 2016. He earned a Master’s degree in Medical Biotechnology in 2010, (110/110 cum laude,) and Ph.D. in Microbiology, Immunology, and Related Diseases in 2014, from the University of Rome "Tor Vergata”. He was appointed to a post-doctoral position at the Laboratory of Tumor Immunology and Biology (LTIB) at the National Cancer Institute, NIH, USA in 2014, where he performed original research including the Evaluation of Antibody-dependent cellular cytotoxicity (ADCC) activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells (EMD-Serono Inc), the generation and analyses of recombinant adenovirus vaccines as an immunotherapeutic against cancer cells (Etubics Corp.), and the effect of HDAC inhibition on tumor sensitivity to NK-mediated killing. He was awarded a Federal Technology Transfer Award at NIH in 2016. The results of his studies have been published in more than 30 peer-reviewed journals, for which he also received the Antonio and Elena De Luca Young Scientist Award by the Italian Cultural Society of Washington D.C. for excellence by an Italian scientist in the D.C. region in 2017. He serves as a reviewer for multiple peer-reviewed scientific journals in the field of immunotherapy of cancer and serves as Associate Editor of the Cancer Molecular Targets and Therapeutics section of the journal Frontiers in Oncology.